Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice

• Published in: mBio Vol. 13; no. 1; p. e0325221
• Main Authors: Peng, Shiwen, Xing, Deyin, Ferrall, Louise, Tsai, Ya-Chea, Roden, Richard B S, Hung, Chien-Fu, Wu, T-C
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 22.02.2022
• Subjects: Animals; CD8-Positive T-Lymphocytes; Epitopes, T-Lymphocyte; Head and Neck Neoplasms; Histocompatibility Antigens Class I - metabolism; HLA-A2 Antigen; HPV16; human papillomavirus; Human papillomavirus 16 - metabolism; Humans; Immunology; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oncogene Proteins, Viral; OPSCC; oral tumor model; Papillomavirus E7 Proteins; Papillomavirus Infections; Research Article; Squamous Cell Carcinoma of Head and Neck; oral tumor model; E6; E7; OPSCC; human papillomavirus; HPV16
• ISSN: 2150-7511; 2150-7511
• DOI: 10.1128/mbio.03252-21

Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is a growing global health problem. HPV16 has been attributed to a majority of HPV-associated HNSCCs. In order to test candidate immunotherapies, we developed a spontaneous HPV16-driven HNSCC model in HLA-A2 (AAD) transgenic mice. We sought to eliminate the confounding effects of dominant HPV antigen presentation through murine major histocompatibility complex class I (MHC-I) via epitope mutagenesis (without compromising tumorigenicity). We generated HPV16 E6(R55K)(delK75) and E7(N53S) expression constructs with mutations in known dominant H-2D epitopes and characterized their presentation through murine and human MHC-I molecules using and activation of HPV16 E6/E7 antigen-specific CD8 T cells. In addition, we tested the ability of E6(R55K)(delK75) and E7(N53S) for oncogenicity. The mutated E7(N53S) abolished the presentation of murine H-2D -restricted HPV16 E7 peptide (i.e., amino acids [aa] 49 to 57) cytotoxic T lymphocyte (CTL) epitope and resulted in HLA-A2-restricted presentation of the HPV16 E7 (aa 11 to 20)-specific CTL epitope. The mutated E6(R55K)(delK75) abolished the activation of murine MHC-I-restricted E6-specific CD8 T cell-mediated immune responses in C57BL/6 mice. In addition, the vaccination led to the activation of human HLA-A2-restricted E6-specific CD8 T cell-mediated immune responses in HLA-A2 (AAD) transgenic mice. Injection of DNA plasmids encoding LucE7(N53S)E6(R55K)(delK75), AKT, c-Myc, and SB100 followed by electroporation results in development of squamous cell carcinoma in the oral/pharyngeal cavity of all of the HLA-A2 (AAD) transgenic mice (5/5), with 2/5 tumor-bearing mice developing metastatic carcinoma in the neck lymph nodes. Our data indicate that mutated HPV16 E6(R55K)(delK75) and mutated HPV16 E7(N53S) DNA abolishes the presentation of HPV16 E6 and E7 through murine MHC-I and results in their presentation through human HLA-A2 molecules. Additionally, the mutated HPV16 E6 and E7 remain oncogenic. Our approach is potentially applicable to different human MHC-I transgenic mice for the identification of human MHC-I restricted HPV16 E6/E7-specific CTL epitopes as well as the generation of spontaneous HPV E6/E7-expressing oral/pharyngeal carcinoma.